Oxford Asset Management’s Carisma Therapeutics CARM Stock Holding History

Oxford Asset Management’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-8,460	Closed	-$176K	–	387
2019 Q4	$176K	Buy	+8,460	New	+$194K	﹤0.01%	1570
2019 Q1	–	Sell	-8,602	Closed	-$244K	–	1679
2018 Q4	$244K	Buy	+8,602	New	+$274K	0.01%	1474
2017 Q3	–	Sell	-691	Closed	-$22K	–	1539
2017 Q2	$22K	Buy	+691	New	+$23K	﹤0.01%	1437
2017 Q1	–	Sell	-8,981	Closed	-$343K	–	1396
2016 Q4	$343K	Buy	+8,981	New	+$396K	0.01%	644

Other funds holding CARM

TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Oxford Asset Management's CARM Position: Q1 2020 in Review

Oxford Asset Management sold out of Carisma Therapeutics (CARM) in Q1 2020, closing a stake of 8,460 shares — an estimated $176K sold.

Oxford Asset Management first reported a position in CARM in Q4 2016 and held it in 4 quarters. The position peaked at $343K in Q4 2016. 36 funds tracked by Wall St. Rank hold CARM as of Q1 2020.

Oxford Asset Management reported no remaining Carisma Therapeutics position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 8,460 Carisma Therapeutics shares in Q1 2020, an estimated $176K.
Oxford Asset Management first reported a position in Carisma Therapeutics in Q4 2016 and held it in 4 quarters.
Oxford Asset Management's Carisma Therapeutics position peaked at $343K in Q4 2016.
36 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.